Product Pathways - PathScan ELISA
PathScan® Phospho-EGF Receptor (Tyr1173) Sandwich ELISA Kit #7187
| Kit Includes | Volume | Solution Color |
|---|---|---|
| EGF Receptor mouse mAb coated microwells | 96 tests | |
| Phospho-EGF Receptor (Tyr1173) Detection Ab | 11 milliliters | Green |
| Anti-rabbit IgG HRP-Linked Ab | 11 milliliters | Red |
| TMB Substrate | 11 milliliters | Colorless |
| STOP Solution | 11 milliliters | Colorless |
| Sealing Tape | 2 sheets | |
| 20X Wash Buffer | 25 milliliters | Colorless |
| Sample Diluent | 25 milliliters | Blue |
| Cell Lysis Buffer (10X) # 9803 | 15 milliliters | Yellowish |
Note: 12 8-well modules –Each module is designed to break apart for 8 tests.
Note: Kit should be stored at 4°C with the exception of Cell Lysis Buffer (10X), which is stored at –20°C (packaged separately).
Species Cross-Reactivity
H
Reactivity Key: H=Human
Description
CST's PathScan® Phospho-EGF Receptor (Tyr1173) Sandwich ELISA Kit is a solid phase sandwich enzyme-linked immunosorbent assay (ELISA) that detects endogenous levels of phospho-EGF Receptor (Tyr1173) protein. An EGF Receptor Mouse mAb #2255* has been coated onto the microwells. After incubation with cell lysates, both phospho- and nonphospho-EGF Receptor proteins are captured by the coated antibody. Following extensive washing, Phospho-EGF Receptor (Tyr1173) Rabbit mAb #4407* is added to detect the captured phospho-EGF Receptor protein. Anti-rabbit IgG, HRP-linked Antibody #7074* is then used to recognize the bound detection antibody. HRP substrate, TMB, is added to develop color. The magnitude of optical density for this developed color is proportional to the quantity of phospho-EGF Receptor (Tyr1173) protein.* Antibodies in kit are custom formulations specific to kit.
Specificity / Sensitivity
CST's PathScan® Phospho-EGF Receptor (Tyr1173) Sandwich ELISA Kit detects endogenous levels of phospho-EGF Receptor (Tyr1173) protein. As shown in Figure 1, using the Phospho-EGF Receptor (Tyr1173) ELISA Kit #7187, a significant induction of Phospho-EGF Receptor (Tyr1173) in A431 cells treated with EGF is detected. However, the levels of total EGF Receptor (phospho and non-phospho) detected by PathScan® Total EGF Receptor Sandwich ELISA Kit #7250, remain unchanged (Figure 1).
Western Blotting
Figure 1: Treatment of A431 cells with EGF stimulates phosphorylation of EGF Receptor at Tyr1173, detected by PathScan® Phospho-EGF Receptor (Tyr1173) Sandwich ELISA kit #7187, but does not affect the level of total EGF Receptor detected by PathScan® Total EGF Receptor Sandwich ELISA kit #7250. OD 450 nm readings are shown in the top figure, while the corresponding Western blot using Phospho-EGF Receptor (Tyr1173) Rabbit mAb #4407 (right panel) or EGF Receptor Antibody #2232 (left panel), is shown in the bottom figure.
Background
The epidermal growth factor (EGF) receptor is a 170 kDa transmembrane tyrosine kinase that belongs to the HER/ErbB protein family. Ligand binding results in receptor dimerization, autophosphorylation, activation of downstream signaling and lysosomal degradation (1,2). Phosphorylation of EGF receptor (EGFR) at Tyr845 in the kinase domain is implicated in stabilizing the activation loop, maintaining the active state enzyme and providing a binding surface for substrate proteins (3,4). c-Src is involved in phosphorylation of EGFR at Tyr845 (5). The SH2 domain of PLCγ binds at phospho-Tyr992, resulting in activation of PLCγ-mediated downstream signaling (6). Phosphorylation of EGFR at Tyr1045 creates a major docking site for c-Cbl, an adaptor protein that leads to receptor ubiquitination and degradation following EGFR activation (7,8). The GRB2 adaptor protein binds activated EGFR at phospho-Tyr1068 (9). A pair of phosphorylated residues (Tyr1148 and Tyr1173) provides a docking site for the SHC scaffold protein, with both sites involved in MAP kinase signaling activation (2). Phosphorylation of EGFR at specific serine and threonine residues attenuates EGFR kinase activity. EGFR carboxy-terminal residues Ser1046 and Ser1047 are phosphorylated by CaM kinase II; mutations to either of these serines results in upregulated EGFR tyrosine autokinase activity (10).
- Hackel, P.O. et al. (1999) Curr. Opin. Cell Biol. 11, 184-189.
- Zwick, E. et al. (1999) Trends Pharmacol. Sci. 20, 408-412.
- Cooper, J.A. and Howell, B. (1993) Cell 73, 1051-1054.
- Hubbard, S.R. et al. (1994) Nature 372, 746-754.
- Biscardi, J.S. et al. (1999) J. Biol. Chem. 274, 8335-8343.
- Emlet, D.R. et al. (1997) J. Biol. Chem. 272, 4079-4086.
- Levkowitz, G. et al. (1999) Mol. Cell 4, 1029-1040.
- Ettenberg, S.A. et al. (1999) Oncogene 18, 1855-1866.
- Rojas, M. et al. (1996) J. Biol. Chem. 271, 27456-27461.
- Feinmesser, R.L. et al. (1999) J. Biol. Chem. 274, 16168-16173.
Application References
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!